HC Wainwright reaffirmed their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report released on Monday, Benzinga reports. The firm currently has a $100.00 target price on the stock. HC Wainwright also issued estimates for Keros Therapeutics’ Q3 2023 earnings at ($1.46) EPS, Q4 2023 earnings at ($1.28) EPS, […]
Keros Therapeutics (KROS) Buy Rating Reiterated at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) issued its earnings results on Monday. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.07, Briefing.com reports. During the same period in the previous year, the company earned ($1.13) EPS. Keros Therapeutics Stock Down 8.7 % Shares of NASDAQ:KROS opened at […]
Keros Therapeutics (NASDAQ:KROS – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.07, Briefing.com reports. During the same quarter last year, the firm earned ($1.13) earnings per share. Keros Therapeutics Price Performance NASDAQ:KROS traded down […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) shares fell 9.7% during trading on Tuesday . The stock traded as low as $36.50 and last traded at $36.50. 118,932 shares changed hands during trading, a decline of 44% from the average session volume of 213,125 shares. The stock had previously closed at $40.42. Analysts Set […]